Daewoong Pharmaceutical Co. LTD.
227
17
28
118
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
4.8%
11 terminated/withdrawn out of 227 trials
91.5%
+5.0% vs industry average
34%
77 trials in Phase 3/4
3%
3 of 118 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (227)
Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis
Role: collaborator
A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia
Role: lead
CART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension
Role: collaborator
Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice
Role: lead
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)
Role: collaborator
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
Role: lead
Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer
Role: lead
Noseguard for Prevention of Respiratory Infections in Real-World Use
Role: lead
Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy
Role: collaborator
A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension
Role: lead
Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer
Role: lead
Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults
Role: lead
Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension
Role: lead
Study Comparing Fexuprazan and Esomeprazole in Patients With Gastroesophageal Reflux Disease
Role: collaborator
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
Role: collaborator
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
Role: collaborator
Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions
Role: lead
ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement
Role: collaborator
Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori
Role: lead
Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.
Role: lead